Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
The current molecular classification divides breast cancer into four major subtypes, including luminal A, luminal B, HER2-positive, and basal-like, based on receptor gene expression profiling. Luminal A and luminal B are hormone receptor (HR, estrogen, and/or progesterone receptor)-positive and are...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/4/1303 |
| _version_ | 1797621856374620160 |
|---|---|
| author | William Sebastian Lauren Forchette Kelsey Donoughe Yibei Lun Anisha Verma Tuoen Liu |
| author_facet | William Sebastian Lauren Forchette Kelsey Donoughe Yibei Lun Anisha Verma Tuoen Liu |
| author_sort | William Sebastian |
| collection | DOAJ |
| description | The current molecular classification divides breast cancer into four major subtypes, including luminal A, luminal B, HER2-positive, and basal-like, based on receptor gene expression profiling. Luminal A and luminal B are hormone receptor (HR, estrogen, and/or progesterone receptor)-positive and are the most common subtypes, accounting for around 50–60% and 15–20% of the total breast cancer cases, respectively. The drug treatment for HR-positive breast cancer includes endocrine therapy, HER2-targeted therapy (depending on the HER2 status), and chemotherapy (depending on the risk of recurrence). In this review, in addition to classification, we focused on discussing the important aspects of HR-positive breast cancer, including HR structure and signaling, genetics, including epigenetics and gene mutations, gene expression-based assays, the traditional and new drugs for treatment, and novel or new uses of technology in diagnosis and treatment. Particularly, we have summarized the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer and compared four common gene expression-based assays that are used in breast cancer as prognostic and/or predictive tools in detail, including their clinical use, the factors being evaluated, patient demographics, and the scoring systems. All these topic discussions have not been fully described and summarized within other research or review articles. |
| first_indexed | 2024-03-11T09:01:59Z |
| format | Article |
| id | doaj.art-6c824090c913457d91eb52dc153d5bd6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:01:59Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6c824090c913457d91eb52dc153d5bd62023-11-16T19:39:07ZengMDPI AGCancers2072-66942023-02-01154130310.3390/cancers15041303Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast CancerWilliam Sebastian0Lauren Forchette1Kelsey Donoughe2Yibei Lun3Anisha Verma4Tuoen Liu5West Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAWest Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAWest Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAWest Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAWest Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAWest Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USAThe current molecular classification divides breast cancer into four major subtypes, including luminal A, luminal B, HER2-positive, and basal-like, based on receptor gene expression profiling. Luminal A and luminal B are hormone receptor (HR, estrogen, and/or progesterone receptor)-positive and are the most common subtypes, accounting for around 50–60% and 15–20% of the total breast cancer cases, respectively. The drug treatment for HR-positive breast cancer includes endocrine therapy, HER2-targeted therapy (depending on the HER2 status), and chemotherapy (depending on the risk of recurrence). In this review, in addition to classification, we focused on discussing the important aspects of HR-positive breast cancer, including HR structure and signaling, genetics, including epigenetics and gene mutations, gene expression-based assays, the traditional and new drugs for treatment, and novel or new uses of technology in diagnosis and treatment. Particularly, we have summarized the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer and compared four common gene expression-based assays that are used in breast cancer as prognostic and/or predictive tools in detail, including their clinical use, the factors being evaluated, patient demographics, and the scoring systems. All these topic discussions have not been fully described and summarized within other research or review articles.https://www.mdpi.com/2072-6694/15/4/1303breast cancerhormone receptorestrogen receptorendocrine therapydrug treatmentgenetics |
| spellingShingle | William Sebastian Lauren Forchette Kelsey Donoughe Yibei Lun Anisha Verma Tuoen Liu Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer Cancers breast cancer hormone receptor estrogen receptor endocrine therapy drug treatment genetics |
| title | Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer |
| title_full | Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer |
| title_fullStr | Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer |
| title_full_unstemmed | Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer |
| title_short | Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer |
| title_sort | genetics treatment and new technologies of hormone receptor positive breast cancer |
| topic | breast cancer hormone receptor estrogen receptor endocrine therapy drug treatment genetics |
| url | https://www.mdpi.com/2072-6694/15/4/1303 |
| work_keys_str_mv | AT williamsebastian geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer AT laurenforchette geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer AT kelseydonoughe geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer AT yibeilun geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer AT anishaverma geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer AT tuoenliu geneticstreatmentandnewtechnologiesofhormonereceptorpositivebreastcancer |